X

This site uses cookies. These cookies collect information about how visitors use a website, for instance which pages visitors go to most often, and if they get error messages from web pages. These cookies don’t collect information that identifies a visitor. All information these cookies collect is used only to improve the website. By visiting this website, you agree that we can place these types of cookies on your device.

Life, changing.
More than 900,000 cancer patients worldwide have used our Oncotype DX tests to personalise treatments and improve outcomes.
Our Mission
Genomic Health’s mission is to transform treatment decisions and outcomes in cancer by delivering clinically actionable diagnostics and services.
Landmark TAILORx Results
The long-awaited results of the Trial Assigning IndividuaLized Options for Treatment (TAILORx) definitively identified a vast majority of women with early stage breast cancer who will receive no benefit from chemotherapy, and the minority for whom chemotherapy can be life-saving.

Making An Impact

Genomic Health is leading in the precision medicine revolution to eliminate the "one-size-fits-all" approach to cancer treatment.
Predicting Cancer Outcomes
Oncotype DX leads industry as only test proven to predict chemotherapy benefit and with prospective clinical outcomes data in more than 50,000 breast cancer patients worldwide.
TAILORx: Transforming the Treatment of Breast Cancer

The long-awaited results of the Trial Assigning IndividuaLized Options for Treatment (TAILORx) definitively identified the vast majority of women with early stage breast cancer who will receive no benefit from chemotherapy, and the minority for whom chemotherapy can be life-saving.

World Class Commercial Channel
We deliver over 400 Oncotype DX test results per day to more than 90 countries through our centralised clinical laboratory, serving physicians and patients with our industry-leading customer service team and more than 200 sales and managed care representatives around the world.
Broadening Access for Patients Worldwide
Genomic Health is dedicated to securing access to ensure cancer patients around the world have access to our clinically actionable Oncotype DX tests. Outside the U.S., there are over 260 million lives covered and growing. The Oncotype DX prostate cancer test is now covered by Medicare in the U.S. for qualified patients, giving nearly 60,000 prostate cancer patients the opportunity to personalise their cancer treatment.
Unsurpassed Scientific and Clinical Expertise
Our expertise consistently demonstrates to physicians, patients and payors that our tests are improving treatment decisions and outcomes, providing significant benefit from both a care and cost perspective.
“I was determined to educate myself about all of my options, and thanks to Oncotype DX, I have not lost any sleep or been worried since I decided to go on active surveillance based on my very low GPS result.”

Dan W.

© 2018 Genomic Health, All rights reserved.

In the US and certain other jurisdictions, Genomic Health, Oncotype DX, Oncotype IQ, and Recurrence Score are registered trademarks, and Genomic Prostate Score and AR-V7 Nucleus Detect are pending registered trademarks, of Genomic Health, Inc.